EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Patient‐derived tumor organoids exhibit high predictive accuracy and clinical promise across cancers: A systematic review and meta‐analysis

Sijia Li, Jiameng Xie, Ziyang Wu, Liyan Miao, Chenrong Huang

Bioengineering & Translational Medicine · 16.11.2026

DOI: 10.1002/btm2.70188 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 16.11.2026. Verfasst von Sijia Li und 4 weiteren Autor:innen. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient‐derived tumor organoids (PDTOs) have emerged as a promising functional platform for precision oncology, yet their clinical translation remains constrained by heterogeneous evidence and insufficient methodological standardization. This study systematically reviewed the clinical utility and limitations of PDTO‐based drug sensitivity testing across different cancer types and treatment settings. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched from inception to June 18, 2026, and studies or registered clinical trials evaluating associations between PDTO drug sensitivity and clinical outcomes were included. A total of 54 studies and 97 registered clinical trials involving 17 cancer types were identified. The establishment success rates of PDTOs ranged from 31.25% to 100.00%, and drug sensitivity was predominantly evaluated using cell viability assays, although response thresholds varied considerably across studies. Quantitative synthesis of 31 studies showed that PDTO‐based drug sensitivity testing achieved a pooled sensitivity of 0.91 (95% CI, 0.83–0.95), specificity of 0.79 (95% CI, 0.65–0.88), and SROC AUC of 0.93 (95% CI, 0.90–0.95) for predicting treatment response. Concordance between PDTO predictions and clinical responses ranged from 53.33% to 100.00%, and PDTO sensitivity appeared to be associated with long‐term survival outcomes. Registered clinical trials encompassed 21 cancer types and were mainly observational, with most studies still ongoing. Overall, PDTOs show considerable potential as a functional drug sensitivity testing approach for predicting treatment response and guiding personalized therapy selection. However, further prospective validation, harmonization of methodologies, and standardized evaluation criteria are required before their widespread implementation in precision oncology.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, S., Xie, J., Wu, Z., Miao, L., & Huang, C. (2026). Patient‐derived tumor organoids exhibit high predictive accuracy and clinical promise across cancers: A systematic review and meta‐analysis. Bioengineering & Translational Medicine. https://doi.org/10.1002/btm2.70188

Vancouver

Li S, Xie J, Wu Z, Miao L, Huang C. Patient‐derived tumor organoids exhibit high predictive accuracy and clinical promise across cancers: A systematic review and meta‐analysis. Bioengineering & Translational Medicine. 2026. doi:10.1002/btm2.70188

BibTeX
@article{Li2026,
  author = {Li, Sijia and Xie, Jiameng and Wu, Ziyang and Miao, Liyan and Huang, Chenrong},
  title = {Patient‐derived tumor organoids exhibit high predictive accuracy and clinical promise across cancers: A systematic review and meta‐analysis},
  journal = {Bioengineering & Translational Medicine},
  year = {2026},
  doi = {10.1002/btm2.70188}
}
Kostenlos starten →